Russia’s health ministry has registered the one-shot Sputnik-Light version of its COVID-19 vaccine for use, the TASS news agency reported on Monday.
Russia said last week that it had completed clinical trials for the slimmed-down vaccine, which it has cast as a possible temporary solution to help countries with high infection rates make the vaccine go further.
Moscow has said that its two-dose Sputnik V vaccine will remain the main version used in Russia.
Earlier on Monday, Russia’s RDIF sovereign wealth fund and China’s Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia’s Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.